-
more
R & D
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)
-
more
Management / Finance
Announcement on Financial Results for FY2025
-
more
R & D
Ono Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting
-
more
R & D
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
-
more
R & D
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
